NASDAQ · AXDX
Healthcare · Medical - Devices
$0.03
Up+$0.00 (+0.00%)
Updated Aug 15, 2026, 3:09 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
AXDX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning AXDX.
AXDX research
Company profile and research snapshot.
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 1, 2024 | Craig-Hallum | Hold | — |
| Mar 9, 2022 | Craig-Hallum | Hold | — |
| Oct 8, 2020 | BTIG | Neutral | — |
| Aug 10, 2020 | Piper Sandler | Overweight | — |
| Sep 27, 2019 | JP Morgan | Underweight | — |
No generated briefing is available yet.
Benzinga · Mar 21, 2025
Accelerate Diagnostics has submitted its Accelerate WAVE system and positive blood culture gram-negative test kit to the FDA for 510(k) clearance. The WAVE system is designed to provide rapid antimicrobial susceptibility testing, enabling faster targeted antimicrobial therapy for patients with serious infections.
GlobeNewswire Inc. · Jan 28, 2025
The global antimicrobial susceptibility testing market is projected to grow at a CAGR of 3.6% from 2025 to 2035, reaching $4.8 billion by 2035. The growth is driven by rising antibiotic resistance, advancements in diagnostic technologies, and government initiatives to combat antimicrobial resistance.
Benzinga · Oct 25, 2024
Accelerate Diagnostics, Inc. (AXDX) announced that it will host a conference call on November 7, 2024, to review its 2024 third quarter results. The company provides solutions for antibiotic resistance and sepsis.
Zacks Investment Research · Nov 29, 2023
Accelerate Diagnostics' (AXDX) Arc system eliminates the need for overnight culture incubation, drastically reducing the wait time for identification results.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AXDX.
No results
No recent SID articles mention AXDX.
